L. Telep

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Erwan L'Her, Alexander Zoufaly, Marco Massari, 2020, The New England journal of medicine.

Compassionate Use of Remdesivir in Children With Severe COVID-19

A. Chokkalingam, M. Das, A. Camacho-González, 2021, Pediatrics.

Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019

A. Chokkalingam, M. Das, O. Manuel, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Letter: direct‐acting anti‐viral (DAA) therapy needs strong safety and efficacy check—authors’ reply

M. Buti, A. Chokkalingam, K. Reddy, 2018, Alimentary pharmacology & therapeutics.

Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment

H. Ramroth, A. Chokkalingam, K. Reddy, 2022, Alimentary pharmacology & therapeutics.

Direct‐acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study

M. Buti, A. Chokkalingam, K. Reddy, 2018, Alimentary pharmacology & therapeutics.

Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States

H. Ramroth, W. Kim, A. Chokkalingam, 2022, Alimentary pharmacology & therapeutics.

Risk of total non-hepatic cancer following treatment for HCV infection with direct-acting antiviral agents

A. Chokkalingam, D. Brainard, A. Osinusi, 2018 .

No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data

A. Chokkalingam, K. Reddy, D. Brainard, 2017 .